Literature DB >> 1662289

Distribution of topoisomerase II cleavage sites in simian virus 40 DNA and the effects of drugs.

Y Pommier1, G Capranico, A Orr, K W Kohn.   

Abstract

The distributions of DNA cleavage sites induced by topoisomerase II in the presence or absence of specific drugs were mapped in the simian virus 40 genome. The drugs studied were 5-iminodaunorubicin, amsacrine (m-AMSA), teniposide (VM-26) and 2-methyl-9-hydroxyellipticinium; each produced a distinctive pattern of enhanced cleavage. Consistently intense cleavage, both in the presence and in the absence of drugs, occurred in the nuclear matrix-associated region. Since topoisomerase II is a major constituent of the nuclear matrix, and cleavage complexes include a covalent link between topoisomerase II and DNA, the findings suggest that topoisomerase II may function to attach DNA to the nuclear matrix. Cleavage usually occurred on both DNA strands with the expected four base-pair 5' stagger, and strong sites tended to occur within A/T runs such as have been associated with binding to the nuclear scaffold. Intense cleavage was present also in the replication termination region, but was absent from the vicinity of the replication origin. Cleavage intensities were found to change with time in a manner that depended both on the site and on the drug, suggesting that topoisomerase II can move along the DNA from a kinetically preferred site to a thermodynamically preferred site.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1662289     DOI: 10.1016/0022-2836(91)90585-t

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  13 in total

1.  DNA topoisomerase II sites in the histone H4 gene during the highly synchronous cell cycle of Physarum polycephalum.

Authors:  V Borde; M Duguet
Journal:  Nucleic Acids Res       Date:  1998-05-01       Impact factor: 16.971

2.  Distribution of topoisomerase II-mediated cleavage sites and relation to structural and functional landmarks in 830 kb of Drosophila DNA.

Authors:  R Miassod; S V Razin; R Hancock
Journal:  Nucleic Acids Res       Date:  1997-06-01       Impact factor: 16.971

Review 3.  DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.

Authors:  Y Pommier
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.

Authors:  I I Gromova; B Thomsen; S V Razin
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

5.  Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.

Authors:  B D Lovett; L Lo Nigro; E F Rappaport; I A Blair; N Osheroff; N Zheng; M D Megonigal; W R Williams; P C Nowell; C A Felix
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-07       Impact factor: 11.205

Review 6.  Interfacial inhibitors: targeting macromolecular complexes.

Authors:  Yves Pommier; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2011-12-16       Impact factor: 84.694

Review 7.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

Review 8.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

9.  Induction of cleavage in topoisomerase I c-DNA by topoisomerase I enzymes from calf thymus and wheat germ in the presence and absence of camptothecin.

Authors:  A Tanizawa; K W Kohn; Y Pommier
Journal:  Nucleic Acids Res       Date:  1993-11-11       Impact factor: 16.971

10.  Position-specific trapping of topoisomerase II by benzo[a]pyrene diol epoxide adducts: implications for interactions with intercalating anticancer agents.

Authors:  Qasim A Khan; Glenda Kohlhagen; Richard Marshall; Caroline A Austin; Govind P Kalena; Heiko Kroth; Jane M Sayer; Donald M Jerina; Yves Pommier
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.